Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16468465 | 1.00 | POLB (0.46) | POLBLMNATP53MAPT | |
| SCHEMBL16468052 | 1.00 | POLB (0.46) | POLBLMNATP53MAPT | |
| SCHEMBL16611937 | 0.87 | POLB (0.47) | POLBLMNATP53MAPT | |
| SCHEMBL16491300 | 0.86 | USP30 (0.45) | POLBLMNATP53MAPT | |
| SCHEMBL16491303 | 0.86 | USP30 (0.45) | POLBLMNATP53MAPT | |
| SCHEMBL16623052 | 0.85 | CA12 (0.41) | POLBLMNATP53MAPT | |
| SCHEMBL16468271 | 0.84 | POLB (0.50) | POLBLMNATP53MAPT | |
| SCHEMBL16612292 | 0.84 | POLB (0.39) | POLBLMNATP53MAPT | |
| SCHEMBL16468315 | 0.84 | USP30 (0.45) | POLBLMNATP53MAPT | |
| SCHEMBL16612234 | 0.83 | TP53 (0.44) | POLBLMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751887-B2 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20160046639-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-18 | — | — | US | disclosed |
| US-9187489-B2 | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| EP-2857404-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20150051190-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051190-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | ROS1, JAK1, ERBB2 | POLB 3415/4885LMNA 3763/4885TP53 930/4885 |
| US-20160046639-A1 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | ROS1, JAK1, ERBB2 | POLB 3415/4885LMNA 3763/4885TP53 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.